Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many administration/handling and missed-dose instructions provided by the AI are not verifiable from the supplied FDA label excerpts. Several safety-critical labeled requirements (e.g., TB screening, vaccination guidance, infection precautions, avoiding live vaccines) are missing, and the provided list includes potentially label-dependent details (e.g., injection site specifics, pen temperature) that are not supported by the excerpts.
Category Scores
Accurate Statements
The dosing schedule for Cosentyx depends on the condition being treated.
Supported in principle by label section 2.3 (recommended dosage differs by indication and patient population), though the excerpt provided does not explicitly state the exact wording.
The prescriber sets the start and maintenance schedule for Cosentyx.
Supported generally by label requirement that COSENTYX is for use under the guidance and supervision of a healthcare provider (2.2).
If a missed Cosentyx dose is close to the next scheduled dose, the missed dose should be skipped and the regular schedule resumed.
Not verifiable from supplied excerpts (no missed-dose instructions in provided label text).
Unsupported Statements
Cosentyx pen should be taken out of the fridge and allowed to reach room temperature before injection.
Not supported by the provided label excerpts.
Cosentyx pen should not be warmed with heat before injection.
Not supported by the provided label excerpts.
The liquid in the Cosentyx pen should be clear to slightly opalescent and colorless to light yellow.
Not supported by the provided label excerpts.
Cosentyx pen should not be used if the liquid is cloudy, has particles, or is discolored.
Not supported by the provided label excerpts.
Common Cosentyx injection sites include the front of the thighs or the abdomen.
Not supported by the provided label excerpts.
Cosentyx should not be injected into the 2-inch/5 cm area around the belly button.
Not supported by the provided label excerpts.
Injection sites should be rotated each time Cosentyx is injected.
Not supported by the provided label excerpts.
The skin should be cleaned with an alcohol swab and allowed to dry before injection.
Not supported by the provided label excerpts.
The pen’s instructions for activating the dose should be followed.
Not supported by the provided label excerpts (no device activation instructions included in supplied text).
The pen should be placed against the skin at the injection site and pressed as directed to deliver the medication.
Not supported by the provided label excerpts.
The pen should be kept in place for the full injection time described for the pen model.
Not supported by the provided label excerpts.
After injection, the site may be gently pressed if needed.
Not supported by the provided label excerpts.
After injection, the injection site should not be rubbed.
Not supported by the provided label excerpts.
Used Cosentyx pens should be disposed of promptly in a puncture-resistant sharps container.
Not supported by the provided label excerpts.
Patients should follow the prescriber’s Cosentyx schedule rather than switching on their own.
Not directly supported by supplied excerpts; while general guidance/supervision is present (2.2), the specific instruction to not switch on their own is not stated.
Patients should call a prescriber or pharmacist for guidance if they are unsure about missed-dose timing.
Not supported by the provided label excerpts.
Repeated Cosentyx injections in the same area can increase irritation, redness, or discomfort.
Not supported by the provided label excerpts.
After Cosentyx injection, mild skin redness, itching, pain, or swelling at the site may occur.
Not supported by the provided label excerpts.
Medical care should be sought promptly for signs of a serious allergic reaction with Cosentyx, such as trouble breathing, facial/lip swelling, or widespread hives.
Not supported by the provided label excerpts (postmarketing immune system reactions are listed, but the specific symptom examples and urgency instruction are not included in the supplied text).
Cosentyx pens are typically stored in a refrigerator.
Not supported by the provided label excerpts (storage instructions not included in supplied text).
Cosentyx pens should be kept in their original packaging to protect from light.
Not supported by the provided label excerpts.
Cosentyx pens should not be frozen.
Not supported by the provided label excerpts.
Cosentyx pen designs may differ depending on formulation and country.
Not supported by the provided label excerpts.
The safest approach is to follow the specific instructions that come with the pen and the dosage form provided by the pharmacist.
Not supported by the provided label excerpts (though it is generally consistent with 'under the guidance... healthcare provider' in 2.2, the exact statement is not present).
The liquid in the Cosentyx pen should be clear to slightly opalescent and colorless to light yellow.
Not supported by the provided label excerpts.
Cosentyx should be used exactly as instructed by a clinician.
Partially consistent with 2.2 (use under guidance), but the exact phrasing and certainty are not directly supported by supplied excerpts.
Contradictions
Important Omissions
Pre-treatment evaluation for active or latent tuberculosis (TB), including that COSENTYX initiation is not recommended in active TB and that latent TB should be treated prior to initiation.
Importance:
High
Vaccination guidance prior to initiating therapy, including avoiding live vaccines in patients treated with COSENTYX.
Importance:
High
Infection warning details: COSENTYX may increase risk of infections; if a serious infection occurs, monitor closely and discontinue until infection resolves; caution regarding opportunistic infections.
Importance:
High
Contraindication statement: contraindicated in patients with previous serious hypersensitivity reaction to secukinumab or excipients.
Importance:
High
Drug interaction management: consideration of CYP450 substrate monitoring and dosage adjustment upon initiation/discontinuation in patients receiving concomitant CYP450 substrates.
Importance:
Moderate
IBD warning: exercise caution and monitor for signs/symptoms of IBD exacerbations.
Importance:
Moderate
Indication alignment: the AI response does not mention that COSENTYX is indicated for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
Importance:
Moderate
Adverse reactions breadth: label includes infection rates and postmarketing immune system reactions and opportunistic infections; AI response only mentions localized reactions and serious allergic-reaction symptoms without reflecting label-listed categories.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Although many device/site handling statements are provided, key label-required safety steps (TB screening, vaccination/live vaccine avoidance, and infection precautions/discontinuation guidance) are omitted from the AI-generated content based on the supplied excerpts, creating a moderate risk of incomplete or unsafe use guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several specific administration/device handling, injection site, and storage details are not supported by the provided label excerpts, and multiple label-critical safety requirements (TB, immunizations/live vaccine avoidance, and infection precautions) are omitted.
Suggested Improvement
Limit administration details to those explicitly supported by the provided FDA label excerpts (or supplied Instructions for Use text) and add the label-required pre-treatment evaluations (TB), immunization/live vaccine avoidance, and infection/serious infection discontinuation guidance.